STOCK MARKET BSE NSE

EU drug agency recommends approving anti-inflammatory medicine to treat severe COVID cases

The Amsterdam-based EMA said it can now be used on adult COVID-19 patients who are being treated with corticosteroids and require supplemental oxygen or mechanical ventilation.

Published: 07th December 2021 08:20 AM  |   Last Updated: 07th December 2021 08:20 AM   |  A+A-

Coronavirus

Coronavirus (Photo | AP)

By PTI

THE HAGUE: The European Union's drugs agency on Monday recommended approving the use of an anti-inflammatory medicine to treat adults hospitalized with severe COVID-19.

The European Medicines Agency decision, which has to be confirmed by the EU's executive commission, extends the use of the drug RoActemra, made by Swiss pharmaceuticals giant Roche, that is currently used to treat forms of arthritis.

The Amsterdam-based EMA said it can now be used on adult COVID-19 patients who are being treated with corticosteroids and require supplemental oxygen or mechanical ventilation.

The drug, given through an IV, tamps down a protein called interleukin-6 that's often found in excess in COVID-19 patients.

The agency said a study of 4,116 hospitalised adults with severe COVID-19 showed that treatment with RoActemra in addition to standard treatment reduced the risk of death when compared with standard treatment alone.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp